Anti-CD73 Antibody Induces Adaptive B Cell Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer immunotherapies using monoclonal antibodies face challenges due to rapid mutation rates in tumor cells, leading to reduced efficacy and relapse, as the surface expression of antigens targeted by these antibodies changes frequently.
Innovation Solution
Administration of an anti-CD73 antibody comprising specific CDR regions (1E9 CDR L1, 1E9 CDR L2, 1E9 CDR L3, 1E9 CDR H1, and 1E9 CDR H2) to patients, followed by isolating and expressing cancer or infectious disease antigen-binding antibodies from B cells to produce effective antibodies for treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monoclonal antibodies target surface antigens on tumor cells, then tumor cell death is invoked through blocking ligand-receptor pathways and ADCC/CMC/ADCP mechanisms, but the rapid mutation rate of tumor cell genes causes surface antigen expression to change rapidly, resulting in treatment non-response or relapse
Solution Approach 1:
The patent transitions from static, fixed-target antibody therapies to dynamic, adaptive antibody therapies. The method involves administering an initial anti-CD73 antibody to stimulate B cells to produce diverse antigen-binding antibodies that can adapt to changing tumor antigen expressions over time, creating a dynamic response that evolves with the tumor
Solution Approach 2:
The patent changes the parameter of antibody specificity from fixed to variable. By using CD73 as a universal trigger to induce diverse B cell responses, the system generates antibodies with varying specificities that can target different tumor antigens as they mutate, effectively changing the targeting parameter dynamically
2Reliability
If anti-CD73 antibody is administered to stimulate B cell production of antigen-binding antibodies, then treatment effectiveness is improved through enhanced antibody production and memory B cell responses, but the complexity of the treatment protocol increases with isolation and expression steps
Solution Approach 1:
The patent applies self-service by using the patient's own B cells to produce the therapeutic antibodies. The anti-CD73 antibody stimulates the patient's B cells to self-produce diverse antigen-binding antibodies, eliminating the need for external antibody sourcing or complex manufacturing processes
Solution Approach 2:
The patent uses CD73 as an intermediary molecule. The anti-CD73 antibody binds to CD73 on B cells, serving as a mediator that triggers the B cells to produce diverse antigen-binding antibodies, simplifying the overall treatment mechanism
Data Source
AI summary
The anti-CD73 antibodies, compositions, and methods provided herein allow, inter alia, for the treatment of cancer and infectious diseases (e.g., bacterial, viral, fungal, parasitic), and for the generation of antigen-specific antibodies in vivo in a subject. Applicants have surprisingly found that administration of an anti-CD73 antibody (e.g., CPI-006) to a subject induces differentiation of B cells and robust expansion of specific B cell clones in the subject. The methods and compositions provided herein are, inter alia, useful for a variety of applications, including personalized medicine.